Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP3 | P05413 | 2/20 | 0.47 |
| ▸ | FABP4 | P15090 | 2/20 | 0.47 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.41 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | RXRA | P19793 | 1/20 | 0.40 |
| ▸ | RXRB | P28702 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.40 |
| ▸ | RXRG | P48443 | 1/20 | 0.40 |
| ▸ | PPARD | Q03181 | 1/20 | 0.40 |
| ▸ | PPARA | Q07869 | 1/20 | 0.40 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.39 |
| ▸ | C1R | P00736 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6108087 | 0.73 | CSF1R (0.53) | CYP2C9 | |
| SCHEMBL5929643 | 0.71 | MAPT (0.65) | — | |
| SCHEMBL8569897 | 0.69 | LMNA (0.43) | MEN1KMT2A | |
| SCHEMBL4433976 | 0.69 | CSF1R (0.48) | FABP3FABP4FABP5CSNK2A1 | |
| SCHEMBL6293298 | 0.68 | FABP3 (0.61) | FABP3FABP4FABP5MEN1KMT2A | |
| Acetic Acid SCHEMBL21725059 | 0.67 | PTGS2 (0.61) | FABP3FABP4MEN1KMT2APTGS2 | |
| SCHEMBL6109140 | 0.66 | FABP3 (0.40) | FABP3FABP4FABP5MEN1KMT2A | |
| SCHEMBL537930 | 0.65 | FABP4 (0.46) | FABP3FABP4FABP5MEN1KMT2A | |
| SCHEMBL28636337 | 0.65 | PPARA (0.41) | FABP3FABP4FABP5MEN1KMT2A | |
| SCHEMBL11545050 | 0.65 | FABP4 (0.64) | FABP3FABP4FABP5MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060173034-A1 | Novel 4-anilinoquinoline-3-carboxamides | ASTRAZENECA AB (SE) | 2006-08-03 | — | — | US | disclosed |
| US-7037925-B2 | 4-anilinoquinoline-3-carboxamides | ASTRAZENECA AB (SE) | 2006-05-02 | — | — | US | disclosed |
| EP-1387830-A1 | NOVEL 4-ANILINOQUINOLINE-3-CARBOXAMIDES | AstraZeneca AB (SE) | 2004-02-11 | — | — | EP | disclosed |
| WO-2002092571-A1 | NOVEL 4-ANILINOQUINOLINE-3-CARBOXAMIDES | ASTRAZENECA AB (SE) | 2002-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173034-A1 | Novel 4-anilinoquinoline-3-carboxamides | JAK3, JAK2, JAK1 | FABP3 2197/4885FABP4 3563/4885FABP5 3852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.